Breakthrough Therapy Designation was granted for the treatment of adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC) who have had prior treatment ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback